Evidence map›Paper›PMID 41145514›Full record

ArticleNature communications2025

DNA methylation patterns facilitate tracing the origin of neuroendocrine neoplasms.

Benjamin Goeppert, Alphonse Charbel, Reka Toth, Yue Zhang, Danial Tabbakh, Thomas Albrecht, Daniel Schrimpf, Louis de Mestier, Jérôme Cros, Monika Nadja Vogel and 10 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Thymic neuroendocrine tumours: molecular landscape, immune microenvironment and therapeutic perspectives.European respiratory review : an official journal of the European Respiratory Society · 2026
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Benjamin GoeppertInstitute of Pathology, Heidelberg University, Medical Faculty, University Hospital Heidelberg, Heidelberg, Germany. Benjamin.Goeppert@rkh-gesundheit.de.ORCID http://orcid.org/0000-0002-4135-9250
Alphonse CharbelInstitute of Pathology, Heidelberg University, Medical Faculty, University Hospital Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-7383-1898
Reka TothLuxembourg Institute of Health, Department of Cancer Research, Strassen, Luxembourg.ORCID http://orcid.org/0000-0002-6096-1052
Yue ZhangLuxembourg Institute of Health, Department of Cancer Research, Strassen, Luxembourg.
Danial TabbakhLuxembourg Institute of Health, Department of Cancer Research, Strassen, Luxembourg.
Thomas AlbrechtInstitute of Pathology, Heidelberg University, Medical Faculty, University Hospital Heidelberg, Heidelberg, Germany.
Daniel SchrimpfClinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Louis de MestierUniversité Paris-Cité, Department of Pancreatology and Digestive Oncology, Beaujon Hospital (APHP) and INSERM U1149, Clichy, France.
Jérôme CrosUniversité Paris-Cité, Department of Pathology, Beaujon Hospital (APHP) and INSERM U1149, Clichy, France.ORCID http://orcid.org/0000-0002-4935-3865
Monika Nadja VogelDiagnostic and Interventional Radiology, Thoraxklinik at University Hospital Heidelberg, Heidelberg, Germany.
De-Hua ChangLiver Cancer Center Heidelberg (LCCH), Heidelberg, Germany.
Eva-Marie BohnInstitute of Pathology, Heidelberg University, Medical Faculty, University Hospital Heidelberg, Heidelberg, Germany.
Alexander BrobeilInstitute of Pathology, Heidelberg University, Medical Faculty, University Hospital Heidelberg, Heidelberg, Germany.
Junfang JiThe MOE Key Laboratory of Biosystems Homeostasis & Protection, Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, and Innovation Center for Cell Signaling Network, Life Sciences Institute, Zhejiang University, Hangzhou, China.ORCID http://orcid.org/0000-0002-3071-6494
Stephan SingerInstitute of Pathology and Neuropathology, Eberhard-Karls University, Tuebingen, Germany.
Petr V NazarovLuxembourg Institute of Health, Department of Cancer Research, Strassen, Luxembourg.ORCID http://orcid.org/0000-0003-3443-0298
Aurel PerrenInstitute of Tissue Medicine and Pathology, University of Berne, Berne, Switzerland.ORCID http://orcid.org/0000-0002-6819-6092
Leonidas ApostolidisLiver Cancer Center Heidelberg (LCCH), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-6358-8206
Andreas von DeimlingClinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-5863-540X
Stephanie RoesslerInstitute of Pathology, Heidelberg University, Medical Faculty, University Hospital Heidelberg, Heidelberg, Germany. Stephanie.Roessler@med.uni-heidelberg.de.ORCID http://orcid.org/0000-0002-5333-5942

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) 314905040Deutsche Forschungsgemeinschaft (German Research Foundation) 469332207Deutsche Forschungsgemeinschaft (German Research Foundation) 493697503Deutsche Krebshilfe (German Cancer Aid) 70113922
6 · The paper itself

Abstract

Neuroendocrine neoplasms (NEN) are thought to originate from diffuse neuroendocrine networks and therefore most frequently arise in the gastrointestinal tract and lungs. The liver is a frequent site of metastasis of NEN but also the existence of primary hepatic NEN has been proposed. Due to the impact on disease management, it is urgently required to discriminate the origin of hepatic NEN metastases and to identify clinically relevant subgroups. Using a comprehensive set of NEN (N = 212) from two independent cohorts, we show that the DNA methylation profiles of NEN of distinct anatomical localizations differ significantly and primary tumor-metastasis pairs cluster together, enabling the identification of the tumor origin. Furthermore, the subgroup of hepatic NEN without clinically detectable primary tumor, thus classified as primary hepatic NEN, does not form a distinct cluster by DNA methylation analysis but colocalizes with various subgroups of extrahepatic NEN. Organ-specific subtyping of NEN delineates a foregut-like epigenetic profile for hepatic NEN with unknown primary. We propose a classifier with high prediction accuracy for each of the different organ sites. In conclusion, our results demonstrate that DNA methylation profiling enables precise prediction of NEN origin and suggests that a substantial proportion of presumed primary hepatic NEN may in fact represent misclassified secondary hepatic NEN of unknown primary.

Indexed as

DNA MethylationLiver NeoplasmsNeuroendocrine TumorsAdultAgedEpigenesis, GeneticFemaleHumansMaleMiddle AgedNeoplasms, Unknown Primary

Identifiers

PMID41145514
PMCPMC12559432

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.